Laurent Phely
YOU?
Author Swipe
View article: CD19/CD22 CAR-T cells in adult patients with relapsed/refractory B-cell malignancies
CD19/CD22 CAR-T cells in adult patients with relapsed/refractory B-cell malignancies Open
Background: Dual-targeted CAR-T cell therapies may help overcome mechanisms of resistance associated with antigen escape. We evaluated an investigational, autologous CD19/CD22-targeted second-generation CAR construct incorporating a 4-1BB …
View article: Real-world data of azacitidine for relapsed/refractory nodal T-follicular helper cell lymphoma in 11 patients
Real-world data of azacitidine for relapsed/refractory nodal T-follicular helper cell lymphoma in 11 patients Open
Relapsed or refractory (r/r) nodal T-follicular helper cell lymphoma of the angioimmunoblastic type is a rare disease with a dismal prognosis. This disease usually harbors mutations in epigenetic modifiers. A standard of treatment for an r…
View article: Modeling the t(2;5) Translocation of Anaplastic Large Cell Lymphoma Using CRISPR-Mediated Chromosomal Engineering
Modeling the t(2;5) Translocation of Anaplastic Large Cell Lymphoma Using CRISPR-Mediated Chromosomal Engineering Open
Background/Objectives: ALK+ Anaplastic Large Cell Lymphoma (ALCL) is an aggressive T-cell lymphoma that is characterized by expression of the Anaplastic Lymphoma Kinase (ALK), which is induced by the t(2;5) chromosomal rearrangement, leadi…
View article: Modeling the t(2; 5) Translocation of Anaplastic Large Cell Lymphoma Using CRISPR-Mediated Chromosomal Engineering
Modeling the t(2; 5) Translocation of Anaplastic Large Cell Lymphoma Using CRISPR-Mediated Chromosomal Engineering Open
ALK+ Anaplastic Large Cell Lymphoma (ALCL) is an aggressive T-cell lymphoma that is characterized by expression of the Anaplastic Lymphoma Kinase (ALK), which is induced by the t(2;5) chromosomal rearrangement leading to the expression of …
View article: Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution
Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution Open
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in treating relapsed and refractory (R/R) B-cell neoplasms, such as diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Despite its success, t…
View article: Dual CD19/CD22-Targeting CAR-T Cells for Richter Transformation: A Case Series
Dual CD19/CD22-Targeting CAR-T Cells for Richter Transformation: A Case Series Open
Introduction Patients with Richter's transformation (RT) of chronic lymphocytic leukemia (CLL) to diffuse large B cell lymphoma (DLBCL) show poor prognosis despite complex chemotherapy and hematopoietic cell transplantation (HCT). Targeted…
View article: Long-Term Immunological Consequences of CD19 CAR T Cell Therapy: Analysis of Infectious Complications and Immune Reconstitution
Long-Term Immunological Consequences of CD19 CAR T Cell Therapy: Analysis of Infectious Complications and Immune Reconstitution Open
Introduction Anti-CD19 chimeric antigen receptor (CAR) T cells have been a major improvement for the treatment of relapsed and refractory B cell neoplasia. Despite its success, the long-term effects and sequela of CAR T cells on the immune…
View article: Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome
Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome Open
Superior outcome of upfront allogeneic hematopoietic
View article: Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia Open
This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.